Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PREVANTICS MAXI SWABSTICK vs SOTRADECOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Not applicable (topical antiseptic with no systemic absorption).
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.
First aid antiseptic for minor cuts, scrapes, and burns
Uncomplicated spider veins (telangiectasias) and reticular veins of the lower extremities,Small, uncomplicated varicose veins
Not applicable. Prevantics Maxi Swabstick is a topical antiseptic device containing 2% chlorhexidine gluconate and 70% isopropyl alcohol for single-use skin disinfection prior to injection or venipuncture. No systemic dosing.
0.5 m L per injection site, multiple sites per session; maximum volume 10 m L per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.
Terminal elimination half-life is 8-12 hours in patients with normal renal function; clinical context: dosing interval adjustment recommended in renal impairment.
Terminal elimination half-life approximately 5-6 hours; clinical effect persists longer due to local action at injection site
Not metabolized (topical application only).
Sodium tetradecyl sulfate is primarily metabolized in the liver via sulfation and glucuronidation, with involvement of hepatic enzymes such as sulfotransferases and UDP-glucuronosyltransferases (UGTs).
Renal excretion of unchanged drug accounts for approximately 65% of elimination; biliary/fecal excretion constitutes about 30%.
Primarily renal; <1% recovered as unchanged drug in urine; majority eliminated as metabolites via bile into feces
Approximately 85-90% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein).
>90% bound to plasma proteins, primarily albumin
Vd is 0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
0.15-0.3 L/kg; reflects limited distribution primarily to plasma and interstitial space
Topical: minimal systemic absorption (<5%); not administered orally or intravenously.
Not applicable; administered via intradermal, intravenous, or endoscopic injection; not intended for oral administration
Not required. No systemic absorption from topical application.
No specific dose adjustment provided in labeling; not studied in renal impairment; use caution in severe impairment.
Not required. No systemic absorption from topical application.
No specific dose adjustment provided in labeling; caution in Child-Pugh class C due to potential for acute hepatic necrosis.
Use as directed for skin antisepsis in children. Apply to intact skin for 30 seconds and allow to dry. Avoid use in infants <2 months due to risk of skin irritation.
Safety and efficacy not established in pediatric patients (age <18 years).
Use as directed for skin antisepsis. No dose adjustment needed. Caution in frail elderly with thin skin to avoid excessive irritation.
No specific dose adjustment required; consider comorbidities and overall health status.
None
Sotradecol injection is contraindicated for the treatment of patients with underlying arterial disease or with known allergy to the drug. Severe adverse reactions including anaphylaxis, pulmonary embolism, and tissue necrosis have been reported.
For external use only,Avoid contact with eyes,Do not use on deep wounds or animal bites,Discontinue if irritation occurs
Anaphylactic reactions; arterial injection causing tissue necrosis; pulmonary embolism; allergy to the drug; use with caution in patients with thrombophlebitis, hypercoagulable states, or chronic obstructive pulmonary disease; avoid extravasation.
Known hypersensitivity to any ingredient
Known allergy to sodium tetradecyl sulfate; acute thrombophlebitis; severe chronic venous insufficiency; arterial disease; uncontrolled diabetes mellitus; sepsis; pregnancy; breastfeeding; incompetent perforating veins.
No known food interactions with topical use. Avoid alcohol consumption immediately after application as it may increase systemic absorption.
No specific food interactions are known. Patients should maintain adequate hydration and avoid excessive alcohol intake, which may increase the risk of bleeding or thrombosis. No dietary restrictions are required.
No evidence of teratogenicity in animal studies; insufficient human data. Avoid during first trimester unless benefit outweighs risk.
FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third trimester: risk of fetal bradycardia, arrhythmias, or death due to systemic absorption if injected near cervix.
Unknown if excreted in breast milk; M/P ratio not determined. Use caution, consider risk-benefit.
Unknown excretion in human milk. Due to low systemic absorption after local injection, risk to breastfed infant is likely low. Caution recommended; M/P ratio not established.
No pharmacokinetic data available; no dose adjustment recommended.
No dose adjustment required; however, use only when clearly needed. Systemic absorption is minimal after local injection, and pharmacokinetic changes in pregnancy are unlikely to alter efficacy or safety.
PREVANTICS MAXI SWABSTICK is a topical antiseptic applicator containing 5% lidocaine and 0.5% phenylephrine for mucosal anesthesia and vasoconstriction. Apply directly to nasal mucosa prior to procedures. Maximum dose: 1 swab per 10 kg body weight. Avoid use in patients with hypertension, hyperthyroidism, or MAOI use. Do not apply to broken skin or eyes.
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent used for the treatment of varicose veins. Administer via direct injection into the vein using a fine needle; avoid extravasation as it causes tissue necrosis. Perform a test dose (0.5 m L) to assess for hypersensitivity. Compression stockings should be worn for 1-3 weeks post-injection. Do not exceed 10 m L per session; maximum total dose per session is 10 m L of 1% or 2 m L of 3% solution. Use caution in patients with arterial disease, recent thrombosis, or known hypersensitivity. Delayed skin pigmentation may occur. Allergic reactions, including anaphylaxis, have been reported.
Do not swallow or ingest the swab solution.,Avoid using more than one swab per application unless directed.,Report any chest pain, palpitations, or severe headache immediately.,Do not drive or operate machinery until numbness resolves.,Keep out of reach of children and pets.
This medication is injected directly into your varicose veins to cause them to collapse and fade.,You may experience a burning sensation at the injection site, which is normal.,Wear compression stockings as directed, typically for 1-3 weeks after treatment.,Avoid strenuous exercise and prolonged standing for 24-48 hours after injection.,Contact your doctor if you develop severe pain, swelling, redness, or skin ulcers at the injection site.,Notify your doctor if you have a history of blood clots, allergies, or are pregnant or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PREVANTICS MAXI SWABSTICK vs SOTRADECOL, answered by our medical review team.
PREVANTICS MAXI SWABSTICK is a Topical Antiseptic that works by Not applicable (topical antiseptic with no systemic absorption).. SOTRADECOL is a Sclerosing agent that works by Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PREVANTICS MAXI SWABSTICK and SOTRADECOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PREVANTICS MAXI SWABSTICK is: Not applicable. Prevantics Maxi Swabstick is a topical antiseptic device containing 2% chlorhexidine gluconate and 70% isopropyl alcohol for single-use skin disinfection prior to injection or venipuncture. No systemic dosing.. The standard adult dose of SOTRADECOL is: 0.5 m L per injection site, multiple sites per session; maximum volume 10 m L per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PREVANTICS MAXI SWABSTICK and SOTRADECOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PREVANTICS MAXI SWABSTICK is classified as Category C. No evidence of teratogenicity in animal studies; insufficient human data. Avoid during first trimester unless benefit outweighs risk.. SOTRADECOL is classified as Category C. FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.